RECURSION PHARMACEUTICALS-A (RXRX)       10.64  -0.1 (-0.93%)

10.64  -0.1 (-0.93%)

US75629V1044 - Common Stock - After market: 10.64 0 (0%)

Buy % Consensus

RXRX was analyzed by 11 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about RXRX.
In the previous month the buy percentage consensus was at a similar level.
RXRX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Analysts have set a mean price target of 17.54. This target is 64.89% above the current price.

Price Target

Price Low Median Mean High 10.648.0810.2017.5439.90 - -24.06% -4.14% 64.89% 275.00%

Up and Down Grades

Date Firm Action Rating
2022-09-16 Keybanc Initiate Overweight
2022-08-11 Goldman Sachs Maintains Neutral
2022-05-24 Goldman Sachs Maintains Neutral
2022-05-12 Goldman Sachs Maintains Neutral
2022-04-18 B of A Securities Downgrade Buy -> Neutral
2022-03-04 SVB Leerink Downgrade Outperform -> Market Perform
2021-12-08 SVB Leerink Maintains Outperform
2021-09-21 Berenberg Initiate Buy
2021-08-16 SVB Leerink Maintains Outperform
2021-05-11 Keybanc Initiate Overweight
2021-05-11 SVB Leerink Initiate Outperform
2021-05-11 JP Morgan Initiate Neutral
2021-05-11 Goldman Sachs Initiate Neutral
2021-05-11 B of A Securities Initiate Buy

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA